

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Jiangsu Hengrui Pharmaceuticals Co., Ltd.

江蘇恒瑞醫藥股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 1276)

OVERSEAS REGULATORY ANNOUNCEMENT

This announcement is made pursuant to the disclosure requirements under Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited.

According to the relevant regulations of the People's Republic of China, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “**Company**”) had published an announcement on the website of the Shanghai Stock Exchange (www.sse.com.cn). The following is a translation of the abovementioned announcement solely for reference only. Should there be any discrepancies, the Chinese version will prevail.

By order of the Board
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
江蘇恒瑞醫藥股份有限公司
Mr. Sun Piaoyang
Chairman

Shanghai, PRC
July 23, 2026

As at the date of this announcement, the Board comprises: (i) Mr. Sun Piaoyang, Mr. Dai Hongbin, Ms. Feng Ji, Mr. Zhang Lianshan, Mr. Jiang Frank Ningjun and Mr. Sun Jieping as executive Directors; (ii) Ms. Guo Congzhao as non-executive Director; and (iii) Mr. Lou Liguang, Mr. Zeng Qingsheng, Mr. Sun Jinyun and Mr. Chow Kyan Mervyn as independent non-executive Directors.

Jiangsu Hengrui Pharmaceuticals Co., Ltd.

Announcement in Relation to the Approval for Drug Registration

The board of directors of the Company and all directors warrant that this announcement does not contain any false information, misleading statement or material omission, and accept legal liability for the truthfulness, accuracy and completeness of the contents herein.

Recently, Jiangsu Hengrui Pharmaceuticals Co., Ltd. (the “Company”) and its subsidiary, Suzhou Suncadia Biopharmaceuticals Co., Ltd., received notification from the National Medical Products Administration (the “NMPA”) approving the market launch of the Company’s innovative drug, camrelizumab for injection in combination with famitinib malate capsules, as a first-line treatment for patients with recurrent or metastatic cervical cancer. With this approval, the targeted immunotherapy combination regimen has now been formally upgraded from second-line (“2L”) to first-line (“1L”) therapy for advanced cervical cancer. The relevant information is hereby announced as follows:

I. Basic Information of the Drug

Drug Name	Camrelizumab for Injection	Famitinib Malate Capsules
Dosage Form	Injection	Capsule
Acceptance No.	CXSS2500104	CXHS2500122
Registration Category	Class 2.2 Therapeutic Biological Product	Chemical Drug Class 2.4
Strength:	200 mg/vial	5 mg
Prescription/Over-the-Counter Drug:	Prescription Drug	
Proposed Indications (or Indications)	Camrelizumab for injection in combination with famitinib malate is indicated for the first-line treatment of patients	

	with recurrent or metastatic cervical cancer who have PD-L1-positive expression (combined positive score (CPS) ≥ 1), as assessed by a fully validated test method.
--	--

II. The Approved Indications of the Drug

Camrelizumab for injection has been approved in China for multiple indications, namely:

1. Indicated for the treatment of advanced hepatocellular carcinoma after sorafenib and/or lenvatinib treatment and/or oxaliplatin-containing chemotherapy.
2. Indicated for use in combination with pemetrexed and carboplatin for 1L treatment for unresectable locally advanced or metastatic epidermal growth factor receptor (EGFR)-mut negative, anaplastic lymphoma kinase (ALK) negative, non-squamous non-small cell lung cancer (NSCLC).
3. Indicated for locally advanced or metastatic esophageal squamous cell carcinoma progressed after or intolerant of 1L chemotherapy.
4. Indicated for the treatment of advanced nasopharyngeal carcinoma progressed after or intolerant of 2L+ chemotherapy.
5. Indicated for use in combination with cisplatin and gemcitabine for 1L treatment for locally relapsed or metastatic nasopharyngeal carcinoma.
6. Indicated for use in combination with cisplatin and paclitaxel for 1L treatment for unresectable locally advanced/relapsed or metastatic esophageal squamous cell carcinoma.
7. Indicated for use in combination with carboplatin and paclitaxel for 1L treatment for locally advanced or metastatic squamous non-small cell lung cancer.
8. Indicated for use in combination with apatinib for 1L treatment for unresectable or metastatic hepatocellular carcinoma.
9. Indicated for use in combination with famitinib malate for patients with recurrent or metastatic cervical cancer who have previously failed platinum-based chemotherapy but have not received bevacizumab treatment.

Famitinib malate capsules were approved in May 2025 for use in combination with camrelizumab for injection in patients with recurrent or metastatic cervical cancer who have failed platinum-based chemotherapy and have not received bevacizumab treatment, and this indication was converted from conditional approval to full approval in July 2026.

III. Other Information of the Drug

Cervical cancer is a malignant tumor that poses a significant threat to women's health. In 2022, China recorded 150,700 new cases and 55,700 deaths from the disease, with both incidence and mortality ranking first among gynecologic cancers in China^[1]. For patients with recurrent or metastatic cervical cancer, first-line treatment is critical to their prognosis and quality of life. Currently, platinum-based chemotherapy (with or without bevacizumab) is the standard first-line regimen recommended by guidelines in China and abroad. However, its efficacy remains limited, and the median overall survival remains unsatisfactory. Therefore, there remains an urgent unmet clinical need for more effective therapies in this setting.

This approval is based on a randomized, open-label, controlled, multi-center phase III clinical study of camrelizumab combined with famitinib malate versus platinum-based chemotherapy in the treatment of recurrent/metastatic cervical cancer (SHR-1210-III-329). A total of 45 study sites in China participated in the study, enrolling 443 patients. All prespecified primary endpoints were met. As of June 10, 2025, the median follow-up in the PD-L1-positive subgroup was 19.5 months, demonstrating that camrelizumab in combination with famitinib malate significantly improved survival benefit in patients with advanced cervical cancer. In the PD-L1-positive population, the median overall survival (OS) was 35.8 months in the combination group versus 23.6 months in the chemotherapy group, corresponding to a significant 36.6% reduction in the risk of death (HR = 0.634)^[2].

Camrelizumab for injection is a humanized anti-PD-1 monoclonal antibody that binds to the human PD-1 receptor and blocks the PD-1/PD-L1 pathway, restoring antitumor immunity and thereby underpinning cancer immunotherapy. Several PD-1 monoclonal antibodies have been approved abroad, including pembrolizumab (Merck, trade name Keytruda), nivolumab (Bristol-Myers Squibb, trade name Opdivo), cemiplimab (Regeneron, trade name Libtayo), and dostarlimab (GlaxoSmithKline, trade name Jemperli). Many similar products have also been approved in China. According to the EvaluatePharma database, global sales of similar products in 2025 amounted to approximately USD 44.605 billion. To date, the total accumulated R&D

investment in projects related to camrelizumab for injection is approximately RMB 3,494.40 million (unaudited).

Famitinib malate capsules are a small-molecule multi-targeted tyrosine kinase inhibitor independently developed by the Company. Several similar products, including sorafenib, sunitinib, and pazopanib, have been approved in China and overseas. According to the EvaluatePharma database, global sales of sorafenib, sunitinib, and pazopanib in 2025 amounted to approximately USD 503 million. To date, the total accumulated R&D investment in projects related to famitinib malate is approximately RMB 291.10 million (unaudited).

IV. Risk Warning

The Company places great importance on drug R&D, and strictly controls the quality and safety throughout the processes of drug R&D, manufacture, and sales. However, post-approval production and sales may be subject to uncertainties. Investors are kindly advised to make prudent decisions and pay attention to investment risks.

Notice is hereby given.

Board of Directors of Jiangsu Hengrui Pharmaceuticals Co., Ltd.

July 23, 2026

[1] Han, B., et al. Cancer incidence and mortality in China, 2022. Journal of the National Cancer Center 4, 47-53 (2024).

[2] Xiaohua Wu. Phase 3 study of camrelizumab plus famitinib versus platinum-based chemotherapy as first-line therapy for recurrent or metastatic cervical cancer. ESMO 2025.